Fundraising FoxNanoptima
1 known investors
Find your way into Nanoptima
Sign up to see every warm intro you have to Nanoptima
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nanoptima team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Nanoptima develops drug delivery technologies for ophthalmic applications, focusing on biomaterial-based solutions for retinal and eye diseases. The company draws on deep pharma and biotech expertise to advance formulation science and delivery mechanisms for pharmaceutical treatments.
Founders & leadership
NW
Ned WakemanCEONed Wakeman founded and leads Nanoptima, which develops biomaterial-based drug delivery technologies for retinal and eye diseases. He has prior experience in life science business development, venture capital, and investment banking, and has directed oncology development programs funded by Cancer Research UK and InnovateUK.
Board
SF
Stephen FromChairman
Investors · 1
Companies House · registry record
View on Companies House ↗- Registered name
- NANOPTIMA LIMITED
- Company number
- 09998528
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 10 Feb 2016
- Registered office
- Suite 21g3, Alderley Park Congleton Road, Nether Alderley, SK10 4TG
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 28 Feb 2025 · next due 30 Nov 2026
- Confirmation statement
- last made up to 4 Jan 2026 · next due 18 Jan 2027
Current officers · 3
- Kevin Pritchard — director, appointed 24 Mar 2022
- Edward Wakeman — director, appointed 10 Feb 2016
- Deepbridge Ned Limited — corporate director, appointed 5 Jun 2026
Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Nanoptima do?
- Nanoptima develops drug delivery technologies for ophthalmic applications, focusing on biomaterial-based solutions for retinal and eye diseases. The company draws on deep pharma and biotech expertise to advance formulation science and delivery mechanisms for pharmaceutical treatments.
- Who are Nanoptima's investors?
- Nanoptima's investors include Deepbridge Capital.